Home

aTyr Pharma, Inc. - Common Stock (ATYR)

0.9622
-0.0978 (-9.23%)
NASDAQ · Last Trade: Oct 13th, 4:10 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close1.060
Open1.065
Bid0.9621
Ask0.9622
Day's Range0.9500 - 1.080
52 Week Range0.6816 - 7.290
Volume8,961,112
Market Cap52.24M
PE Ratio (TTM)-1.218
EPS (TTM)-0.8
Dividend & YieldN/A (N/A)
1 Month Average Volume23,749,003

Chart

About aTyr Pharma, Inc. - Common Stock (ATYR)

aTyr Pharma, Inc. is a biotechnology company focused on developing innovative therapies to address rare diseases by leveraging its proprietary expertise in the biology of tRNA synthetases. The company specializes in advancing treatments that modulate the immune system, with a keen interest in conditions such as neurodegenerative diseases and muscle wasting disorders. aTyr employs a unique platform that seeks to harness the natural functions of these proteins, aiming to deliver potential solutions that improve patients' quality of life and address unmet medical needs. Through rigorous research and clinical development processes, aTyr Pharma strives to bring transformative therapies to market. Read More

News & Press Releases

INVESTOR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) and reminds investors of the December 9, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
By Faruqi & Faruqi, LLP · Via Business Wire · October 12, 2025
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYR
NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · October 12, 2025
ATYR Investor Notice: Robbins LLP Reminds Investors of the Securities Fraud Class Action Against aTyr Pharma, Inc.
SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) --
By Robbins LLP · Via GlobeNewswire · October 10, 2025
Why Is aTyr Stock Falling Today?stocktwits.com
Via Stocktwits · September 15, 2025
aTyr Pharma, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR
The DJS Law Group reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
By DJS Law Group · Via Business Wire · October 10, 2025
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
By The Schall Law Firm · Via Business Wire · October 10, 2025
Rosen Law Firm Urges aTyr Pharma, Inc. (NASDAQ: ATYR) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of aTyr Pharma, Inc. (NASDAQ: ATYR) common stock between January 16, 2025 and September 12, 2025, both dates inclusive (the “Class Period”). aTyr is a clinical stage biotechnology company.
By The Rosen Law Firm, P.A. · Via Business Wire · October 10, 2025
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · October 10, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of aTyr Pharma, Inc. - ATYR
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · September 24, 2025
Benzinga Bulls And Bears: Intel, FedEx, Cracker Barrel — And Markets Close At Record Highsbenzinga.com
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Via Benzinga · September 20, 2025
Top 3 Health Care Stocks That May Explode In Septemberbenzinga.com
Via Benzinga · September 19, 2025
Goldman Sachs To Rally around 9%? Here Are 10 Top Analyst Forecasts For Tuesdaybenzinga.com
Via Benzinga · September 16, 2025
Crude Oil Rises 1%; Manufacturing Activity in New York Falls In Septemberbenzinga.com
Via Benzinga · September 15, 2025
Which stocks are most active on Monday?chartmill.com
Stay updated with the latest market activity on Monday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
Via Chartmill · September 15, 2025
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga.com
Via Benzinga · September 15, 2025
aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR
The DJS Law Group announces that it is investigating claims on behalf of investors of aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of the securities laws.
By DJS Law Group · Via Business Wire · September 15, 2025
ATyr Pharma Stock Sinks, Plans FDA Review After Mixed Phase 3 Resultsbenzinga.com
ATyr Pharma's stock dips after Phase 3 trial of efzofitimod misses steroid reduction goal, but shows improvements in lung function and steroid withdrawal rates.
Via Benzinga · September 15, 2025
Nasdaq Gains Over 100 Points; Tesla Shares Spike Higherbenzinga.com
Via Benzinga · September 15, 2025
New Mountain Finance, Texas Instruments, Analog Devices And Other Big Stocks Moving Lower In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · September 15, 2025
Why Check-Cap Shares Are Trading Higher By 183%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · September 15, 2025
Why Is Atyr Pharma Stock Slipping Premarket?stocktwits.com
Investors braced for imminent Phase 3 EFZO-FIT trial results of efzofitimod, with analysts calling it a key inflection point.
Via Stocktwits · September 15, 2025
1 Small-Cap Biotech Stock Poised for a Breakoutfool.com
The next couple of weeks could reveal a great deal about this stock's prospects.
Via The Motley Fool · September 11, 2025
Nvidia To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Fridaybenzinga.com
Via Benzinga · August 22, 2025
Alerus Financial Posts Better-Than-Expected Earnings, Joins Celcuity, SES AI, Abercrombie & Fitch And Other Big Stocks Moving Higher On Mondaybenzinga.com
Via Benzinga · July 28, 2025
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga.com
Via Benzinga · July 23, 2025